Alkermes plc has received a $150 million milestone payment from Biogen triggered by the U.S. FDA approval of VUMERITY (diroximel fumarate), a novel oral fumarate for the treatment of relapsing forms of multiple sclerosis, and Alkermes’ transfer to Biogen.   “The receipt of this milestone payment marks an important achievement for Alkermes and is a testament to the strategic execution of our clinical and regulatory activities related to VUMERITY over the past few years. This payment...